Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors

J. M. Michot; R. Pruvost; C. Mateus; S. Champiat; A. L. Voisin; A. Marabelle; O. Lambotte

doi:10.1093/annonc/mdx701

Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors

J. M. Michot, R. Pruvost, C. Mateus, S. Champiat, A. L. Voisin, A. Marabelle, O. Lambotte

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

20 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	518-520
Nombre de pages	3
journal	Annals of Oncology
Volume	29
Numéro de publication	2
Les DOIs	https://doi.org/10.1093/annonc/mdx701
état	Publié - 1 févr. 2018

Accès au document

10.1093/annonc/mdx701

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{8bf0878c0df142f3bb89649549ec011c,

title = "Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors",

author = "Michot, {J. M.} and R. Pruvost and C. Mateus and S. Champiat and Voisin, {A. L.} and A. Marabelle and O. Lambotte",

note = "Funding Information: AG: speaker fee from BMS (Bristol Myers Squibb) and travel grant from MSD; AGM: honoraria, grants and travel grants from ViiV Healthcare, Janssen-Cilag, Gilead Sciences and MSD; MAM: personal fees from BMS for participation in boards, personal fees from Lilly, personal fees from MSD, non-financial support from Boehringer, outside the submitted work; BA: No conflict of interest in the cancer and immunotherapy fields; JPS: consultant or advisory role (fees) or meeting invitation from Janssen-Cilag, Roche, BMS, MSD, Pfizer, Novartis, PFO and Gilead. All remaining authors have declared no conflicts interest.",

year = "2018",

month = feb,

day = "1",

doi = "10.1093/annonc/mdx701",

language = "English",

volume = "29",

pages = "518--520",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "2",

}

TY - JOUR

T1 - Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors

AU - Michot, J. M.

AU - Pruvost, R.

AU - Mateus, C.

AU - Champiat, S.

AU - Voisin, A. L.

AU - Marabelle, A.

AU - Lambotte, O.

N1 - Funding Information: AG: speaker fee from BMS (Bristol Myers Squibb) and travel grant from MSD; AGM: honoraria, grants and travel grants from ViiV Healthcare, Janssen-Cilag, Gilead Sciences and MSD; MAM: personal fees from BMS for participation in boards, personal fees from Lilly, personal fees from MSD, non-financial support from Boehringer, outside the submitted work; BA: No conflict of interest in the cancer and immunotherapy fields; JPS: consultant or advisory role (fees) or meeting invitation from Janssen-Cilag, Roche, BMS, MSD, Pfizer, Novartis, PFO and Gilead. All remaining authors have declared no conflicts interest.

PY - 2018/2/1

Y1 - 2018/2/1

UR - http://www.scopus.com/inward/record.url?scp=85042562438&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx701

DO - 10.1093/annonc/mdx701

M3 - Letter

C2 - 29088318

AN - SCOPUS:85042562438

SN - 0923-7534

VL - 29

SP - 518

EP - 520

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -